Literature DB >> 24002614

Validation of an engineered cell model for in vitro and in vivo HIF-1α evaluation by different imaging modalities.

A Lo Dico1, S Valtorta, C Martelli, S Belloli, U Gianelli, D Tosi, S Bosari, A Degrassi, M Russo, I Raccagni, G Lucignani, R M Moresco, L Ottobrini.   

Abstract

PURPOSE: The aim of this study was to characterize a cell-based model for the molecular study of hypoxia-inducible factor (HIF)-1α activity, in the context of hypoxia, by means of different imaging techniques. PROCEDURES: Engineered U251-HRE glioma cells were used to analyze the molecular mechanisms underlying HIF-1α activity in vitro in relation to luciferase expression. The same cells were orthotopically implanted in mice to evaluate tumor progression and hypoxia induction by bioluminescence imaging, fluorescence imaging, positron emission tomography (PET), and magnetic resonance imaging (MRI).
RESULTS: In vitro analyses highlighted the relationship between HIF-1α and luciferase activity in hypoxic conditions and after pharmacological treatments in U251-HRE cells. Through in vivo studies, it was possible to assess hypoxia establishment in relation to tumor growth by optical imaging, PET and MRI.
CONCLUSIONS: The findings of this study indicate that the U251-HRE orthotopic murine model can be used to reliably evaluate processes modulating HIF-1α activity, using both molecular and preclinical non-invasive imaging techniques.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24002614     DOI: 10.1007/s11307-013-0669-0

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  42 in total

1.  Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system.

Authors:  Daniel P Stiehl; Renato Wirthner; Jens Köditz; Patrick Spielmann; Gieri Camenisch; Roland H Wenger
Journal:  J Biol Chem       Date:  2006-06-21       Impact factor: 5.157

2.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

3.  A new precursor for the radiosynthesis of [18F]FLT.

Authors:  S J Martin; J A Eisenbarth; U Wagner-Utermann; W Mier; M Henze; H Pritzkow; U Haberkorn; M Eisenhut
Journal:  Nucl Med Biol       Date:  2002-02       Impact factor: 2.408

4.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

Review 5.  Biological consequences of tumor hypoxia.

Authors:  M Höckel; P Vaupel
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

6.  Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.

Authors:  Dimpy Koul; Ruijun Shen; Sherry Bergh; Xiaoyang Sheng; Shishir Shishodia; Tiffany A Lafortune; Yiling Lu; John F de Groot; Gordon B Mills; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

7.  Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

Authors:  Gerald Reischl; Donna S Dorow; Carleen Cullinane; Andrew Katsifis; Peter Roselt; David Binns; Rodney J Hicks
Journal:  J Pharm Pharm Sci       Date:  2007       Impact factor: 2.327

Review 8.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

9.  Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Authors:  Silvia Valtorta; Sara Belloli; Francesca Sanvito; Valeria Masiello; Giuseppe Di Grigoli; Cristina Monterisi; Ferruccio Fazio; Maria Picchio; Rosa Maria Moresco
Journal:  J Nucl Med       Date:  2013-05-22       Impact factor: 10.057

Review 10.  Cancer modeling: modern imaging applications in the generation of novel animal model systems to study cancer progression and therapy.

Authors:  Alessia Stell; Andrea Biserni; Sara Della Torre; Gianpaolo Rando; Balaji Ramachandran; Luisa Ottobrini; Giovanni Lucignani; Adriana Maggi; Paolo Ciana
Journal:  Int J Biochem Cell Biol       Date:  2007-03-12       Impact factor: 5.085

View more
  9 in total

1.  Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.

Authors:  A Lo Dico; C Martelli; S Valtorta; I Raccagni; C Diceglie; S Belloli; U Gianelli; V Vaira; L S Politi; S Bosari; G Lucignani; R M Moresco; L Ottobrini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-27       Impact factor: 9.236

2.  Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming.

Authors:  Young Chan Chae; Valentina Vaira; M Cecilia Caino; Hsin-Yao Tang; Jae Ho Seo; Andrew V Kossenkov; Luisa Ottobrini; Cristina Martelli; Giovanni Lucignani; Irene Bertolini; Marco Locatelli; Kelly G Bryant; Jagadish C Ghosh; Sofia Lisanti; Bonsu Ku; Silvano Bosari; Lucia R Languino; David W Speicher; Dario C Altieri
Journal:  Cancer Cell       Date:  2016-08-08       Impact factor: 31.743

3.  MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Glioma.

Authors:  Alessia Lo Dico; Viviana Costa; Cristina Martelli; Cecilia Diceglie; Francesca Rajata; Aroldo Rizzo; Carmine Mancone; Marco Tripodi; Luisa Ottobrini; Riccardo Alessandro; Alice Conigliaro
Journal:  Theranostics       Date:  2016-05-08       Impact factor: 11.556

Review 4.  Imaging Modalities to Assess Oxygen Status in Glioblastoma.

Authors:  Aurélien Corroyer-Dulmont; Ararat Chakhoyan; Solène Collet; Lucile Durand; Eric T MacKenzie; Edwige Petit; Myriam Bernaudin; Omar Touzani; Samuel Valable
Journal:  Front Med (Lausanne)       Date:  2015-08-19

Review 5.  Optical imaging probes in oncology.

Authors:  Cristina Martelli; Alessia Lo Dico; Cecilia Diceglie; Giovanni Lucignani; Luisa Ottobrini
Journal:  Oncotarget       Date:  2016-07-26

6.  Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models.

Authors:  Silvia Valtorta; Alessia Lo Dico; Luisa Ottobrini; Rosa Maria Moresco; Isabella Raccagni; Daniela Gaglio; Sara Belloli; Letterio S Politi; Cristina Martelli; Cecilia Diceglie; Marcella Bonanomi; Giulia Ercoli; Valentina Vaira
Journal:  Oncotarget       Date:  2017-12-06

7.  Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide.

Authors:  Alessia Lo Dico; Cristina Martelli; Cecilia Diceglie; Giovanni Lucignani; Luisa Ottobrini
Journal:  Front Oncol       Date:  2018-07-02       Impact factor: 6.244

8.  Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.

Authors:  Alessia Lo Dico; Daniela Salvatore; Cristina Martelli; Dario Ronchi; Cecilia Diceglie; Giovanni Lucignani; Luisa Ottobrini
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

Review 9.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.